Towards Improved Health via Computational Precision Medicine: Learning from Heterogeneous COVID Data

Seminar / Lecture
For NYU Community

X Rays of Lungs


Farah E. Shamout
Assistant Professor & Emerging Scholar of Computer Engineering
NYU Abu Dhabi


In the era of big data and artificial intelligence, computational precision medicine can create opportunities that directly contribute to saving patient lives, improving efficiencies of care providers, and decreasing the high burden of disease and socioeconomic costs. In this talk, Dr. Shamout will provide a high-level overview of the state-of-the-art and recent work on machine learning for healthcare. The focus will be on two flagship projects that were completed during her appointment as an Emerging Scholar at NYU Abu Dhabi, which included (i) deterioration prediction among COVID-19 patients and (ii) breast cancer detection in ultrasound imaging. Finally, she will describe the themes of ongoing work and aims of future plans, in order to advance patient diagnosis and prognosis and promote multidisciplinary contributions in computing and health sciences at NYU.

Dr. Shamout is an Assistant Professor Emerging Scholar in Computer Engineering at NYU Abu Dhabi, where she leads the Clinical Artificial Intelligence Laboratory. She is also an Affiliated Faculty in the Radiology Department at NYU Grossman School of Medicine. Prior to joining NYU Abu Dhabi, Farah completed her DPhil (PhD) in Engineering Science at the University of Oxford as a Rhodes Scholar and was a member of Balliol College. Her research interests lie in using data science and machine learning for real-world clinical problems, multi-modal learning, and mining of electronic health records

Deterioration risk curves generated by the COVID-GMIC-DRC model for patients
Deterioration risk curves (DRCs) generated by the COVID-GMIC-DRC model for patients in the test set with (faded red lines) and without adverse events (faded blue lines). The mean DRC for patients with adverse events (red dashed line) is higher than the DRC for patients without adverse events (blue dashed line) at all times. The graph also includes the ground-truth population DRC (black dashed line) computed from the test data.